Kronos Bio, Inc. (KRON)

NASDAQ: KRON · IEX Real-Time Price · USD
10.68
0.55 (5.43%)
At close: Jan 14, 2022 4:00 PM
10.15
-0.53 (-4.96%)
After-hours:Jan 14, 2022 4:22 PM EST
Market Cap601.79M
Revenue (ttm)n/a
Net Income (ttm)-121.90M
Shares Out56.35M
EPS (ttm)-2.31
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume242,128
Open9.98
Previous Close10.13
Day's Range9.95 - 10.80
52-Week Range9.96 - 33.39
Betan/a
AnalystsBuy
Price Target40.25 (+276.9%)
Earnings DateNov 17, 2021

About KRON

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy...

IndustryBiotechnology
IPO DateOct 9, 2020
Employees95
Stock ExchangeNASDAQ
Ticker SymbolKRON
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Kronos Bio stock is "Buy." The 12-month stock price forecast is 40.25, which is an increase of 276.87% from the latest price.

Price Target
$40.25
(276.87% upside)
Analyst Consensus: Buy

News

Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Di...

Data in the second half of 2023 could potentially lead to accelerated approval If approved, entospletinib would be the first treatment for newly diagnosed patients with the NPM1 mutation who are fit for...

1 month ago - GlobeNewsWire

Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742

Initial data demonstrate long plasma half-life and dose-dependent target inhibition

1 month ago - GlobeNewsWire

Kronos Bio Announces Participation in Upcoming Investor Conferences

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that...

1 month ago - GlobeNewsWire

Kronos Bio Appoints Roshawn Blunt to Board of Directors

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the ...

2 months ago - GlobeNewsWire

Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results

Company today announces progression of two discovery programs within its pipeline

2 months ago - GlobeNewsWire

Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus' Platform

Kronos to receive broad access to Tempus' real-world data and proprietary tools and materials to expand preclinical hypotheses testing capabilities and inform more streamlined clinical trial design

2 months ago - GlobeNewsWire

Kronos Bio Announces Participation in the BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in Oncology

SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced tha...

2 months ago - GlobeNewsWire

Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster...

Preliminary clinical data from Phase 1/2 study still anticipated in Q4 Preliminary clinical data from Phase 1/2 study still anticipated in Q4

3 months ago - GlobeNewsWire

Kronos Bio Reports Recent Business Progress and Second Quarter Financial Results

Announced FDA clearance of Investigational New Drug application (IND) for lanraplenib (LANRA) for treatment of patients with acute myeloid leukemia (AML)

5 months ago - GlobeNewsWire

Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of P...

Company intends to develop LANRA as a once-daily chronic treatment for genetically-defined AML patients

5 months ago - GlobeNewsWire

Kronos Bio to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual R&D Day Today

Unveils development strategy for lanraplenib (LANRA), which will expand addressable patient population for SYK inhibitor portfolio in acute myeloid leukemia (AML); plans to initiate two Phase 1/2 trials...

7 months ago - GlobeNewsWire

Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day

Virtual R&D Day on May 25 to unveil SYK portfolio development strategy and highlight momentum of CDK9 inhibitor program and differentiated drug discovery platform

8 months ago - GlobeNewsWire

Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Grow...

MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition

9 months ago - GlobeNewsWire

Kronos Bio Comments on the Passing of Board Member John C. Martin, Ph.D.

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON) today commented on the passing of John C. Martin, Ph.D., board member and early investor in the...

9 months ago - GlobeNewsWire

Kronos Bio Appoints Taiyin Yang, Ph.D., to Board of Directors

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 26, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the...

9 months ago - GlobeNewsWire

Kronos Bio Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results

Positive End-of-Phase 2 meeting with the FDA for entospletinib in newly diagnosed NPM1-mutated acute myeloid leukemia

9 months ago - GlobeNewsWire

Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an Oral CDK9 Inhibitor T...

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced tha...

10 months ago - GlobeNewsWire

Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute...

Registrational Phase 3 trial will assess measurable residual disease (MRD) negative complete response (CR) as the primary endpoint to support potential accelerated approval

10 months ago - GlobeNewsWire

Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC...

KB-0742 generated using the company's proprietary small molecule microarray (SMM) screening platform

10 months ago - GlobeNewsWire

Kronos Bio Announces Participation in the Cowen 41st Annual Health Care Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced part...

10 months ago - GlobeNewsWire

Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors

SAN MATEO, Calif. and CAMBRIDGE, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the ...

11 months ago - GlobeNewsWire

Kronos Bio Announces FDA Clearance of Investigational New Drug (IND) Application for KB-0742, an Oral CDK9 Inhibitor ...

MYC amplification found in approximately 30% of solid tumors

1 year ago - GlobeNewsWire

Kronos Bio Reports Recent Business Progress and Third Quarter 2020 Financial Results

Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of N PM1-mutated acute myeloid leukemia

1 year ago - GlobeNewsWire

Kronos Bio Announces Participation in the Jefferies Virtual London Healthcare Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that...

1 year ago - GlobeNewsWire

Last Week's Notable Insider Buys: Carnival, Citigroup And More

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other symbols:CCLBAMFUBOHEISTTK
1 year ago - Benzinga